Patent · US Active

Complement component C5 iRNA compositions and methods of use thereof

US11873491B2 · kind B2 · utility

0Cited by

5References

32Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Kevin Fitzgerald · Brookline, US
James Butler · Lynnfield, US
Brian Bettencourt · Groton, US
Anna Borodovsky · Cambridge, US
Satyanarayana Kuchimanchi · Cambridge, US
Klaus Charisse · Acton, US
Muthiah Manoharan · Carlsbad, US
Martin Maier · Cambridge, US
Kallanthottathil G. Rajeev · Wayland, US
Donald C. Foster · Lake Forest Park, US

Key dates

Filing date	Jul 12, 2021
Grant date	Jan 16, 2024
Priority date	—
Expiry date	Aug 1, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.